Table 2.
Antiplatelet/anticoagulant therapy throughout the study period and conventional medical therapy at enrolment in ACS patients with lower or upper quartile on-treatment epinephrine induced platelet aggregations.
| Medical therapy | ||||
|---|---|---|---|---|
| Total cohort (n = 75) | Epinephrine induced aggregations in the LQ (n = 19) | Epinephrine induced aggregations in the UQ (n = 19) | p = | |
| Antiplatelet and anticoagulant therapy | ||||
| ASA, 100 mg | ||||
| At baseline, (%) | 98 | 100 | 95 | 1.00 |
| At 3 months, (%) | 98 | 100 | 95 | 1.00 |
| At 12months, (%) | 98 | 100 | 95 | 1.00 |
| Clopidogrel 75 mg/150 mg | ||||
| At baseline, (%) | 78/7 | 85/10 | 80/10 | 1.00 / 1.00 |
| At 3 months, (%) | 80/0 | 90/0 | 84/0 | 1.00 |
| At 12 months, (%) | 75/0 | 92/0 | 76/0 | 0.81 |
| Prasugrel, 10 mg | ||||
| At baseline, (%) | 13 | 5 | 5 | 1.00 |
| At 3 months, (%) | 17 | 10 | 5 | 1.00 |
| At 12 months, (%) | 10 | 0 | 6 | 1.00 |
| Ticagrelor, 90 mg | ||||
| At baseline, (%) | 2 | 0 | 5 | 1.00 |
| At 3 months, (%) | 2 | 0 | 11 | 0.49 |
| At 12 months, (%) | 2 | 0 | 6 | 1.00 |
| No P2Y12 inhibitor | ||||
| At baseline, (%) | 0 | 0 | 0 | 1.00 |
| At 3 months, (%) | 1 | 0 | 0 | 1.00 |
| At 12 months, (%) | 13 | 8 | 12 | 1.00 |
| VKA | ||||
| At baseline, (%) | 11 | 11 | 11 | 1.00 |
| At 3 months, (%) | 11 | 5 | 5 | 1.00 |
| At 12 months, (%) | 11 | 5 | 5 | 1.00 |
| Medical therapy at enrolment | ||||
| ACE-inhibitor/ARB, (%) | 93/5 | 89/11 | 95/5 | 1.00/1.00 |
| Beta–blocker, (%) | 97 | 100 | 100 | 1.00 |
| CCB, (%) | 5 | 0 | 11 | 0.49 |
| Nitrates, (%) | 19 | 32 | 16 | 0.47 |
| MRA, (%) | 16 | 21 | 26 | 1.00 |
| OAD/insulin, (%) | 15/3 | 11/0 | 11/5 | 1.00 / 1.00 |
| PPI, (%) | 88 | 90 | 90 | 1.00 |
| Diuretics, (%) | 16 | 16 | 5 | 0.61 |
| Statin, | ||||
| At baseline, (%) | 97 | 95 | 95 | 1.00 |
| At 3 months, (%) | 97 | 95 | 100 | 1.00 |
| At 12 months, (%) | 89 | 85 | 88 | 1.00 |
Values are given as percentage of the corresponding total groups. p = showed the statistical difference between the lower quartile and the upper quartile patient groups.
ASA, acetylsalicylic acid; VKA, vitamin K antagonist; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; MRA, mineralocorticoid receptor antagonist; OAD, oral antidiabetic therapy; PPI, proton-pump inhibitor.